The product line will be led by Orchid’s new chemical entity, Orblicef (Cefepime-Enmetazobactum), and others including Ceftaroline and Cefiderocol.
Orchid Pharma’s newly formed antimicrobial solutions division is targeting a turnover of up to Rs 300 crore in the next three years with around 250 strong salespeople on board as it combats the challenge of antimicrobial resistance in India, according to a top company official.
Orchid AMS (Antimicrobial Solutions) aims to partner with approximately 2,500 to 3,000 hospitals and healthcare institutions over the next two to three years to implement effective antimicrobial stewardship programs (AMSP).
Antimicrobial resistance is one of the biggest challenges in healthcare beyond hospitals as drugs are easily available over the counter and antibiotics also reach the country through poultry, fish and crops, Rajnish Rohatgi, CEO of Orchid AMS, a division of Orchid Pharma, told PTI.
“It’s a very important issue. We think not only from a business perspective, but also from a point of view of making a difference, but it gives us a motivating purpose beyond the business realm and giving back to society in our own way, contributing to this issue,” he said of the reasons behind the launch of the new division.
Orchid AMS aims to provide innovative solutions against antimicrobial resistance (AMR) and cover around 3000 hospitals and healthcare institutions over the next 2-3 years. It will facilitate sessions to engage with the healthcare community on AMR in 13 cities by the end of this year.
Asked about the business opportunities, Rohatgi said, “We hope that in three years this division will have around 250 salespeople and we aim to achieve a turnover of Rs 250-300 crore.”
Explaining, he said, “In the next fiscal year 2025-26 we should have around 125 people and we are looking at divisional sales of around Rs 100 crore and reach out to 2,000 hospitals across the country in the first full year of operations, which is fiscal year 2026.”
In terms of products, he said: “In the next two months or so, we will launch around 30 different molecules…”
The product line will be led by Orchid’s new chemical entity, Orblicef (Cefepime-Enmetazobactum), and others including Ceftaroline and Cefiderocol.
The introduction of a wide range of molecules will cover between 2,500 and 3,000 hospitals in the next three years.
Asked about the launch of the products, Rohatgi said the company has already appointed distributors for some of the key cities in North, West and South India. It is yet to do so for Central and East India, which will be in Phase II.
“Right now we are going to be there in Delhi-NCR, Chandigarh, Jaipur in the north; Mumbai and Pune in the west; Bengaluru, Hyderabad, Vijayawada, Vizag, Chennai, Cochin and Coimbatore in the south… Next year, we will add Central India or Eastern India, and we may open more cities in each of the two countries,” he said.
(Only the headline and image of this report may have been reworked by Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
First published: September 22, 2024 | 1:19 PM IS
Disclaimer:
The information contained in this post is for general information purposes only. We make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the post for any purpose.
We respect the intellectual property rights of content creators. If you are the owner of any material featured on our website and have concerns about its use, please contact us. We are committed to addressing any copyright issues promptly and will remove any material within 2 days of receiving a request from the rightful owner.